Back to results
US 2021/0198672 A1Published application
Aptamer for sclerostin and use thereof
AssigneeAptacure Therapeutics Limited
InventorsGe Zhang, Yuanyuan Yu, Shuaijian Ni, Yixin He
Life of this patent
Estimating the term…
Abstract
The invention relates to the field of biomedicine. Specifically, the present invention relates to aptamers against sclerostin and uses thereof, especially uses in the treatment of sclerostin-related diseases such as osteoporosis.
Claims16
An aptamer against sclerostin, wherein the aptamer
- i) comprises a nucleotide sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94% or at least about 95% identity with any one of SEQ ID NOs:
- 1-17, or
- ii) comprises at least 30, at least 35, at least 40, at least 45, at least 50 or more contiguous nucleotides within any one of SEQ ID NOs:
- 1-17,
- preferably, the aptamer comprises a sequence of any one of SEQ ID NOs:
- 1-17 or 19-24,
- wherein the aptamer specifically binds to sclerostin.
4 more elements
(canceled)
(canceled)
Dependencies are inferred from the claim text.